Philip Morris International (PM)
Consumo básico / Tabaco y nicotina
The international tobacco company that transformed into a growing nicotine business: smoke-free products (IQOS + ZYN) already account for 42% of revenue, grow at a double-digit rate, and carry better margins than cigarettes. But at ~$193 (near all-time highs, ~26×) the re-rating from 'value tobacco' to 'growth consumer staple' has already happened: 5-year base ~$213 (+6%/year): Fairly valued — a quality business at a full price, where multiple compression offsets the growth and the dividend (3%) carries the return.
- Price
- $192.90
- Intrinsic value (5y, base)
- $213
- Total annual return (5y)
- 5.6%
- Status (nominal)
- Fairly valued
- Margin of safety
- +5%
The essentials
- The world leader in international tobacco (outside the US) that reinvented itself as a growing nicotine business: smoke-free products —IQOS (heated tobacco) + ZYN (nicotine pouches, from the Swedish Match acquisition)— already account for 41.5% of revenue ($16.9bn), grow ~15% annually, and carry better gross margin (70%) than cigarettes (67.5%). IQOS grew its consumables +11% (155bn units); ZYN +37% (880M cans), with more than 60% of the category in the US.
- Cigarettes (combustible, 58% of revenue) decline in volume (−1.5%) but pricing power sustains revenue — the cash that funds the transition. The FDA authorized in Jun-2026 the marketing of 20 ZYN variants as 'modified risk' (MRTP), the category's first regulatory de-risking. Dividend aristocrat (17 years of increases, 3% yield).
- ⚠️ At ~$193 (~1% off the all-time high) it trades at ~26× — well above pure-play tobacco peers (Altria 13x · BTI 13x) and already in the neighborhood of quality consumer staples (above PepsiCo, near Coca-Cola). The re-rating on the smoke-free story has already happened. It also carries high net debt ($46.5bn, ~2.7x EBITDA, from Swedish Match) that paused buybacks until it deleverages, and negative book equity.
Intrinsic value — two valuation methods
Total return at 5 years: 5.6%/year = 2.0% appreciation + 3.6% dividend. The target price ($213) is ex-dividend; the $36 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $220 · Multiples $203) exceeds the market price ($193).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $193 trades ~4.7% below its value discounted to today (~$203); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($213) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$130.
Thesis
The business
Philip Morris is a quality tobacco company that transformed into a growing nicotine business. Smoke-free products (IQOS + ZYN) already account for 42% of revenue, grow at a double-digit rate, and carry better margins than cigarettes — the mix improves the quality of the business year after year. The moat (brands + addiction + pricing power + regulation that protects incumbents) is wide, and the IQOS-in-the-US optionality remains unopened. It is a top-quality nicotine franchise, with the product's moral controversy as a backdrop.
The valuation
A growth consumer staple is valued on P/E over comparable net income (which gives the equity value directly — earnings are already after interest and taxes). TTM earnings are ~$11.5bn (normalized). At ~$193, that is ~26× on TTM (and ~22.5x on this year's adjusted earnings) — well above pure-play tobacco peers (Altria 13x, BTI 13x) and already in the neighborhood of quality consumer staples (above PepsiCo, near Coca-Cola). The re-rating on the smoke-free story has already materialized.
The base scenario projects earnings growing ~7%/year (smoke-free +high-single-digit margin-accretive growth + combustible pricing power, against the volume decline + the tax rate rising toward 21.5%) toward ~$16bn in five years, at an exit multiple of 20x (the top of the band for a quality consumer staple, with modest compression from ~26x today). That gives ~$213/share → a total return of +6%/year, of which the dividend (3%) is the largest part.
The margin of safety
It trades close to intrinsic value, far from the required margin of safety. At ~$193, near all-time highs, the market already pays for Philip Morris as the growth consumer staple it became — a multiple above PepsiCo and near Coca-Cola, not the declining-tobacco multiple of its peers. The smoke-free growth is real, but it is in the price. The verdict is Fairly valued: a quality business at a full price, where multiple compression (from ~26x toward the top of the consumer-staple band, 20x) offsets much of the earnings growth, leaving the dividend (3%) as the largest part of the return. The bear case (EU/FDA regulatory tightening + accelerating cigarette decline + a tobacco-company multiple) takes the value well below the price; the bull case (IQOS takes off in the US + deleveraging resumes buybacks + the multiple holds) is a substantial upside. The asymmetry is not especially favorable at today's price.
What to watch
Three things. Regulation: it is the central disconfirming factor — the EU tobacco framework review (proposed in 2026) and the risk of the FDA revoking ZYN/IQOS authorizations could hit the smoke-free thesis. Deleveraging: high debt (~2.7x EBITDA) keeps buybacks paused; their resumption (once leverage comes down) would be an additional return driver not in the base case today. And IQOS execution in the US: FDA authorization for IQOS ILUMA would open the world's largest nicotine market — the biggest optionality. ZYN's Q1 2026 decline (channel destocking, not lost demand) is transitory noise, not a break. If the price corrected toward a more reasonable multiple, the quality of the business would make it interesting; at all-time highs, the margin of error is thin.
Educational / informational. Does not constitute investment advice.